{"product_id":"lucisuni-sunitinib","title":"LuciSuni (Sunitinib)","description":"\u003ch2\u003eAbout Sunitinib\u003c\/h2\u003e\u003cp\u003eSunitinib is an anti-cancer medication. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.\u003csup id=\"cite_ref-FDA_3-0\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch3\u003eGastrointestinal Stromal Tumor\u003c\/h3\u003e\u003cp\u003eIndicated for treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate\u003c\/p\u003e\u003cp\u003e50 mg PO qDay for 4 weeks, THEN 2 weeks drug-free, repeat cycle\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eRenal Cell Carcinoma\u003c\/h3\u003e\u003cp\u003eIndicated for treatment of advanced renal cell carcinoma (RCC)\u003c\/p\u003e\u003cp\u003e50 mg PO qDay for 4 weeks, THEN 2 weeks drug-free, repeat cycle\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch4\u003eAdjuvant treatment of RCC\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy\u003c\/li\u003e\n\u003cli\u003e50 mg PO qDay for 4 weeks, THEN 2 weeks drug-free, repeat cycle for a total of nine 6-week cycles\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003ePancreatic Neuroendocrine Tumors\u003c\/h3\u003e\u003cp\u003eIndicated for progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease\u003c\/p\u003e\u003cp\u003e37.5 mg PO qDay continuously without a scheduled off-treatment period\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954752555,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0922.jpg?v=1787022227","url":"https:\/\/xomeds.com\/products\/lucisuni-sunitinib","provider":"XOMEDS","version":"1.0","type":"link"}